Can-Fite Biopharma Ltd (NASDAQ:CANF) Expected to Post Earnings of -$0.80 Per Share

Equities analysts expect Can-Fite Biopharma Ltd (NASDAQ:CANF) to report earnings of ($0.80) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma reported earnings of ($0.90) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The firm is scheduled to issue its next earnings results on Friday, August 30th.

According to Zacks, analysts expect that Can-Fite Biopharma will report full year earnings of ($1.49) per share for the current year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.32) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Can-Fite Biopharma.

Can-Fite Biopharma (NASDAQ:CANF) last released its quarterly earnings results on Wednesday, May 29th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.94) by $0.74. The firm had revenue of $0.30 million during the quarter.

Separately, HC Wainwright reiterated a “buy” rating on shares of Can-Fite Biopharma in a research report on Tuesday, March 26th.

Shares of NASDAQ:CANF traded down $0.05 during trading on Tuesday, reaching $2.94. 4,019 shares of the company traded hands, compared to its average volume of 132,702. Can-Fite Biopharma has a 52 week low of $2.66 and a 52 week high of $25.95.

About Can-Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Featured Story: Holder of Record

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with's FREE daily email newsletter.